Highlights Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 21:00:02 13/02/2026 GMT			5-day change	1st Jan Change
121.41 ^USD	+1.82%		-0.43%	+15.34%

02-13	Merck Shares Rise After Deutsche Bank Upgrade	MT
02-13	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Amid January Consumer Price Inflation Report	MT

Highlights

02-13	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Amid January Consumer Price Inflation Report	MT
02-12	Merck Advances Treatment of Bladder and Kidney Cancers with New Data At 2026 ASCO GU Cancers Symposium	CI
02-11	Sector Update: Health Care Stocks Rise Late Afternoon	MT
02-11	Merck Announces the U.S. Food and Drug Administration Approves KEYTRUDA (Pembrolizumab and Berahyaluronidase Alfa-Pmph) and KEYTRUDA QLEX	CI
02-11	Merck Says US FDA Approves Keytruda Combination in Platinum-Resistant Ovarian Cancer	MT
02-10	FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, primary peritoneal carcinoma	RE
02-10	Calla Lily Clinical Care and Merck Announce Strategic Collaboration to Advance Intravaginal Drug Delivery Platform	CI
02-05	Merck veteran Perlmutter-led Eikon ?Therapeutics valued at $860 million in Nasdaq debut	RE
02-05	Merck veteran Perlmutter-led Eikon ?Therapeutics valued at $860 million in Nasdaq debut	RE
02-05	Merck Says Health Canada Approves Enflonsia for Respiratory Syncytial Virus Prevention in Newborns, Infants	MT
02-05	Merck Announces Health Canada Approval of ENFLONSIA for the Prevention of RSV in Newborns and Infants	CI
02-05	Perlmutter-backed Eikon Therapeutics raises $381.2 million in IPO	RE
02-03	Sector Update: Health Care Stocks Softer Late Afternoon	MT
02-03	Sector Update: Health Care Stocks Lower in Afternoon Trading	MT
02-03	Pfizer Fourth-Quarter Earnings Unexpectedly Rise; COVID-19 Product Sales Plunge	MT
02-03	Top Midday Stories: PayPal Misses Q4 Estimates, Names CEO; Palantir Shares Rise on Strong Results	MT
02-03	Wall St edges higher with earnings deluge in spotlight; Palantir soars	RE
02-03	Merck & Co., Inc. Provides Earnings Guidance for the Full Year 2026	CI
02-03	Sector Update: Health Care Stocks Mixed Premarket Tuesday	MT
02-03	S&P 500, Nasdaq poised for higher open as earnings deluge takes center stage	RE
02-03	Merck's 2026 outlook clouds upbeat fourth-quarter results	RE
02-03	Merck Issues Full-Year Outlook Below Expectations Despite Fourth-Quarter Beat	MT
02-03	US Equity Futures Gain Pre-Bell as Partial Government Shutdown Drags On	MT
02-03	Brace for the Earnings Flood
02-03	Merck & Co., Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Merck to Buy Verona Pharma for About $10B

July 09, 2025 at 05:30 pm